Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa

M. Macho, S. Saha, G. Konert, A. Banerjee, D. Ewe, P. Hrouzek, P. Urajová, K. Saurav

. 2022 ; 10 (6) : e0223222. [pub] 20221027

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22032118

Resistance development and exhaustion of the arsenal of existing antibacterial agents urgently require an alternative approach toward drug discovery. Herein, we report the screening of Medicines for Malaria Venture (MMV) Pandemic Response Box (PRB) through a cascade developed to streamline the potential compounds with antivirulent properties to combat an opportunistic pathogen, Pseudomonas aeruginosa. To find an agent suppressing the production of P. aeruginosa virulence factors, we assessed the potential of the compounds in PRB with quorum sensing inhibitory activity. Our approach led us to identify four compounds with significant inhibition of extracellular virulence factor production and biofilm formation. This provides an opportunity to expand and redirect the application of these data sets toward the development of a drug with unexplored target-based activity. IMPORTANCE The rise of drug-resistant pathogens as well as overuse and misuse of antibiotics threatens modern medicine as the number of effective antimicrobial drugs steadily decreases. Given the nature of antimicrobial resistance development under intense selective pressure such as the one posed by pathogen-eliminating antibiotics, new treatment options which could slow down the emergence of resistance are urgently needed. Antivirulence therapy aims at suppressing a pathogen's ability to cause disease rather than eliminating it, generating significantly lower selective pressure. Quorum sensing inhibitors are thought to be able to downregulate the production of virulence factors, allowing for smaller amounts of antimicrobials to be used and thus preventing the emergence of resistance. The PRB constitutes an unprecedented opportunity to repurpose new as well as known compounds with cytotoxicity and in vitro absorption, distribution, metabolism and excretion (ADME) profile available, thus shortening the time between compound discovery and medicinal use.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032118
003      
CZ-PrNML
005      
20230131151812.0
007      
ta
008      
230120s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1128/spectrum.02232-22 $2 doi
035    __
$a (PubMed)36301146
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Macho, Markéta $u Laboratory of Algal Biotechnology, Institute of Microbiology of the Czech Academy of Sciences-Center Algatech, Třeboň, Czech Republic $u University of South Bohemia, Faculty of Science, České Budějovice, Czech Republic
245    10
$a Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa / $c M. Macho, S. Saha, G. Konert, A. Banerjee, D. Ewe, P. Hrouzek, P. Urajová, K. Saurav
520    9_
$a Resistance development and exhaustion of the arsenal of existing antibacterial agents urgently require an alternative approach toward drug discovery. Herein, we report the screening of Medicines for Malaria Venture (MMV) Pandemic Response Box (PRB) through a cascade developed to streamline the potential compounds with antivirulent properties to combat an opportunistic pathogen, Pseudomonas aeruginosa. To find an agent suppressing the production of P. aeruginosa virulence factors, we assessed the potential of the compounds in PRB with quorum sensing inhibitory activity. Our approach led us to identify four compounds with significant inhibition of extracellular virulence factor production and biofilm formation. This provides an opportunity to expand and redirect the application of these data sets toward the development of a drug with unexplored target-based activity. IMPORTANCE The rise of drug-resistant pathogens as well as overuse and misuse of antibiotics threatens modern medicine as the number of effective antimicrobial drugs steadily decreases. Given the nature of antimicrobial resistance development under intense selective pressure such as the one posed by pathogen-eliminating antibiotics, new treatment options which could slow down the emergence of resistance are urgently needed. Antivirulence therapy aims at suppressing a pathogen's ability to cause disease rather than eliminating it, generating significantly lower selective pressure. Quorum sensing inhibitors are thought to be able to downregulate the production of virulence factors, allowing for smaller amounts of antimicrobials to be used and thus preventing the emergence of resistance. The PRB constitutes an unprecedented opportunity to repurpose new as well as known compounds with cytotoxicity and in vitro absorption, distribution, metabolism and excretion (ADME) profile available, thus shortening the time between compound discovery and medicinal use.
650    12
$a Pseudomonas aeruginosa $7 D011550
650    12
$a biofilmy $7 D018441
650    _2
$a pandemie $7 D058873
650    _2
$a antibakteriální látky $x farmakologie $x metabolismus $7 D000900
650    _2
$a quorum sensing $7 D053038
650    _2
$a faktory virulence $x metabolismus $7 D037521
655    _2
$a časopisecké články $7 D016428
700    1_
$a Saha, Subhasish $u Laboratory of Algal Biotechnology, Institute of Microbiology of the Czech Academy of Sciences-Center Algatech, Třeboň, Czech Republic
700    1_
$a Konert, Grzegorz $u Laboratory of Photosynthesis, Institute of Microbiology of the Czech Academy of Sciences-Center Algatech, Třeboň, Czech Republic
700    1_
$a Banerjee, Avik $u Laboratory of Photosynthesis, Institute of Microbiology of the Czech Academy of Sciences-Center Algatech, Třeboň, Czech Republic
700    1_
$a Ewe, Daniela $u Laboratory of Algal Biotechnology, Institute of Microbiology of the Czech Academy of Sciences-Center Algatech, Třeboň, Czech Republic
700    1_
$a Hrouzek, Pavel $u Laboratory of Algal Biotechnology, Institute of Microbiology of the Czech Academy of Sciences-Center Algatech, Třeboň, Czech Republic $1 https://orcid.org/0000000220610266
700    1_
$a Urajová, Petra $u Laboratory of Algal Biotechnology, Institute of Microbiology of the Czech Academy of Sciences-Center Algatech, Třeboň, Czech Republic
700    1_
$a Saurav, Kumar $u Laboratory of Algal Biotechnology, Institute of Microbiology of the Czech Academy of Sciences-Center Algatech, Třeboň, Czech Republic $1 https://orcid.org/0000000270844204
773    0_
$w MED00209157 $t Microbiology spectrum $x 2165-0497 $g Roč. 10, č. 6 (2022), s. e0223222
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36301146 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151808 $b ABA008
999    __
$a ok $b bmc $g 1891100 $s 1183453
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 10 $c 6 $d e0223222 $e 20221027 $i 2165-0497 $m Microbiology spectrum $n Microbiol Spectr $x MED00209157
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...